Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes

Scandinavian Journal of Immunology

Volumn 69, Issue 2, 2009, Pages 80-89

  Durantez M ^a   Lopez Vazquez A B ^a   De Cerio, A L D ^a   Huarte, E ^a   Casares, N ^a   Prieto, J ^a   Borras Cuesta F ^a   Lasarte, J J ^a   Sarobe, P ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN 571; CARCINOEMBRYONIC ANTIGEN 691; EPITOPE; HLA A2 ANTIGEN; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 2 157; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 112; PLASMID DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; GENE CONSTRUCT; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; MICE; NEOPLASM PROTEINS; PEPTIDES; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 58849146287     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02202.x     Document Type: Article

References (30)

1. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989 7 : 601 24.
2. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008 8 : 351 60.
3. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001 1 : 209 19.
4. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007 21 : 1859 74.
5. Xiang R, Lode HN, Chao TH et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000 97 : 5492 7.
6. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005 23 : 9008 21.
7. Lode HN, Huebener N, Zeng Y, Fest S, Weixler S, Gaedicke G. DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann N Y Acad Sci 2004 1028 : 113 21.
8. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003 9 : 729 35.
9. Depla E, Van der Aa A, Livingston BD et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2008 82 : 435 50.
10. Palmowski MJ, Choi EM, Hermans IF et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002 168 : 4391 8.
11. Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005 23 : 651 82.
12. Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998 59 : 1 14.
13. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997 57 : 4570 7.
14. Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994 1 : 751 61.
15. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991 173 : 1007 15.
16. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997 185 : 2043 51.
17. Zabaleta A, Arribillaga L, Llopiz D et al. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res 2007 74 : 25 35.
18. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977 36 : 59 74.
19. Holzhutter HG, Frommel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999 286 : 1251 65.
20. Theobald M, Ruppert T, Kuckelkorn U et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998 188 : 1017 28.
21. Toes RE, Nussbaum AK, Degermann S et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001 194 : 1 12.
22. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001 19 : 4652 60.
23. Velders MP, Weijzen S, Eiben GL et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001 166 : 5366 73.
24. Morel S, Levy F, Burlet-Schiltz O et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000 12 : 107 17.
25. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002 13 : 95 109.
26. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007 67 : 1842 52.
27. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 2007 37 : 675 85.
28. Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005 175 : 6169 76.
29. Casares N, Lasarte JJ, de Cerio AL et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001 31 : 1780 9.
30. Speiser DE, Lienard D, Pittet MJ et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002 32 : 731 41.